89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma

• Mohammed Al-Zubaidi,
• Elizabeth Liow,
• Dickon Hayne,
• Andrew D Redfern,
• Tom Ferguson,
• Steve McCombie,
• Pravin Viswambaram,
• Nat Lenzo,
• Richard Gauci

Affiliations

Mohammed Al-Zubaidi

Department of Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Elizabeth Liow

Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia

Dickon Hayne

Department of Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Andrew D Redfern

Department of Medical Oncology, Fiona Stanley Hospital, Perth, Australia

Tom Ferguson

Department of Medical Oncology, Fiona Stanley Hospital, Perth, Australia

Steve McCombie

Department of Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Pravin Viswambaram

Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Nat Lenzo

Nuclear Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Richard Gauci

Nuclear Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia